Effect of Using Pictograms on Improving Depression and Anxiety Among Type 2 Diabetic Patients.

Impact of Using Pictograms as an Educational Strategy on Improving Patient Depression and Anxiety Among Low Health Literate Patients With Type 2 Diabetes at Northern Badya Hospital, Jordan.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05822349

Enrollment

204

Registered

2023-04-20

Start date

2023-04-01

Completion date

2023-08-01

Last updated

2023-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

we will study the impact of using pictograms on improving depression and anxiety among type 2 diabetic patients, we suppose that patients who received pictograms-enriched labels will have lower levels of depression and anxiety in comparison with those who will not receive after three month follow-up evaluation.

Interventions

BEHAVIORALpicograms-enriched label

The intervention care includes usual care (instructions for using each anti-diabetic drug) plus pictograms that show how much medications should be taken at each time of day (morning, noon, evening, and night), how to take them in relation to meals, the purpose of the drug, and the most important non-pharmacologic interventions for diabetic patients (weight loss, exercise, avoiding smoking, blood sugar controlling).

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Participants are eligible if they are Jordanian adults, aged 18 or older, who have been clinically diagnosed with T2DM for at least 6 months, having low health literacy (Individuals who obtained 66 or lower scores in the full TOFHLA instrument are considered as individuals with low literacy in the study) \[24\], come personally for the refill.

Exclusion criteria

* Patients who are unable to communicate verbally (aphasic or with hearing impairment), those with any visual, learning disabilities, and psychological or hepatorenal disease (according to the clinical diagnosis by a physician), and those deemed too ill or frail to attend the clinic, and who have participated in other diabetes education research projects will be excluded.

Design outcomes

Primary

Measure	Time frame	Description
change in depression level	12 weeks following ends of intervention	Patient Health Questionnaire-9 (PHQ-9)
change in anxiety level	12 weeks following ends of intervention	Generalized Anxiety Disorder scale (GAD-7)

Countries

Jordan

Contacts

Primary ContactEsraa M AL Sbaihat

israa8190637@yahoo.com0779036395

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026